Venous thromboembolism (VTE) is the third most common cause of vascular mortality
worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

Despite the enthusiasm surrounding novel targeted agents and immunotherapies,
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …

Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …

Background The stratification of outpatients on chemotherapy for breast, colorectal, lung,
and ovarian cancers at risk of venous thromboembolism (VTE) remains an unmet clinical …

In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous
thromboembolism is not recommended. Several risk prediction scores to identify cancer …

Cancer-associated venous thromboembolism (VTE) is a major source of oncologic cost,
morbidity and mortality. Identifying high-risk patients for prophylactic anticoagulation is …

Background Oncology guidelines suggest using the Khorana score to select ambulatory
cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) …

Importance Thromboprophylaxis for individuals receiving systemic anticancer therapies has
proven to be effective. Potential to maximize benefits relies on improved risk-directed …